Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coronado Biosciences has received notice of allowance for US patent application covering CNDO-109, from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The patent is entitled, Method for activating natural killer cells by tumor cell preparation in vitro and has a current expiration date of July 2027.
CNDO-109 activates the immune system’s NK cells to seek and destroy cancer cells.
The biologic,CNDO-109, demonstrated activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer in preclinical studies.
The company plans to begin a Phase 1/2 dose escalation trial in AML patients in the second half of 2012.